BioSpace News Archive

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET.

GRI Bio, Inc. today presented positive preclinical data demonstrating its lead program GRI-0621 reduces the important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).

NeuroSense Therapeutics Ltd., a company developing novel treatments for severe neurodegenerative diseases, announces that Vice President of R&D, Dr. Shiran Zimri will be a key presenter at the ALS Drug Development Summit in Boston, Mass.

The Beyeonics™ Maverick system has been used in surgery for the first time to successfully give surgeons enhanced visual and operational capabilities during neurosurgical and orthopedic procedures.

Ferring Pharmaceuticals today announced three poster presentations at Digestive Disease Week® (DDW 2024) that add to the robust clinical evidence for REBYOTA® (fecal microbiota, live – jslm), including the first real-world outcomes data assessing the use of this therapy in patients with recurrent C. difficile (C. diff) infection.

AIM ImmunoTech Inc. announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences.

Octapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as Vice President of Commercial Development & Marketing, assuming immediate leadership of the product marketing team as the company continues to grow its presence in the U.S. market.

Perosphere Technologies today announced Michael A. Grosso, MD, FACS, joins its Advisory Board.

Danimer Scientific, Inc. announced today that Stephen E. Croskrey has informed the Board of Directors that he will retire as Chief Executive Officer not later than the end of this calendar year.

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel ® ) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA .